{"id":"low-dose-car-t-cells-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAR-T cell therapy involves genetically modifying a patient's own T cells to express synthetic receptors that recognize tumor-associated antigens. Low-dose formulations aim to maintain anti-tumor efficacy while decreasing the incidence and severity of cytokine release syndrome and neurotoxicity associated with standard-dose CAR-T therapy. This approach may improve the therapeutic window by balancing tumor control with tolerability.","oneSentence":"Low-dose CAR-T cells are engineered T lymphocytes expressing chimeric antigen receptors at reduced cell doses to target and kill cancer cells while potentially reducing toxicity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:33.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (specific indication not specified in available data)"}]},"trialDetails":[{"nctId":"NCT07350863","phase":"PHASE1","title":"U69-CART-Cells For R/R T-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-25","conditions":"Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT06875063","phase":"PHASE1","title":"GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-04-30","conditions":"Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell","enrollment":45},{"nctId":"NCT07456371","phase":"PHASE1","title":"PIC1 Injection Therapy for Relapsed/Refractory B-NHL","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2026-03","conditions":"Non-Hodgkin Lymphoma","enrollment":18},{"nctId":"NCT06222853","phase":"PHASE1","title":"Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-02-10","conditions":"Systemic Lupus Erythematosus, CAR-T Cell Therapy","enrollment":22},{"nctId":"NCT07318259","phase":"PHASE1","title":"Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2026-01-26","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT07331467","phase":"PHASE1","title":"Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2026-01","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT07233642","phase":"PHASE1","title":"Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2025-11","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT06248086","phase":"PHASE1","title":"A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-09-06","conditions":"B-cell Lymphoma","enrollment":1},{"nctId":"NCT07184450","phase":"PHASE1","title":"Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2025-09-01","conditions":"Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc)","enrollment":11},{"nctId":"NCT06553898","phase":"PHASE1","title":"Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-08-13","conditions":"Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy","enrollment":18},{"nctId":"NCT06842589","phase":"PHASE1","title":"Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2025-05-14","conditions":"Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy","enrollment":18},{"nctId":"NCT06934447","phase":"PHASE1","title":"Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2025-04-25","conditions":"CAR T Cell Therapy, Systemic Lupus Erythematosus, BCMA","enrollment":18},{"nctId":"NCT06904131","phase":"NA","title":"A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors","status":"RECRUITING","sponsor":"Obstetrics & Gynecology Hospital of Fudan University","startDate":"2025-05-11","conditions":"Gynecological Solid Tumors","enrollment":20},{"nctId":"NCT06904729","phase":"PHASE3","title":"Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children","status":"RECRUITING","sponsor":"Guangzhou Women and Children's Medical Center","startDate":"2025-05-01","conditions":"Lupus Nephritis","enrollment":50},{"nctId":"NCT06758713","phase":"PHASE1","title":"Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Southern Medical University","startDate":"2025-01-15","conditions":"Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy","enrollment":60},{"nctId":"NCT06691152","phase":"PHASE1","title":"Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-10-30","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT06518876","phase":"PHASE1","title":"A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Novatim Immune Therapeutics (Zhejiang) Co., Ltd.","startDate":"2024-08-31","conditions":"POEMS Syndrome","enrollment":21},{"nctId":"NCT06087341","phase":"PHASE1","title":"A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma","status":"RECRUITING","sponsor":"Antonio Pérez Martínez","startDate":"2024-01-10","conditions":"Advanced Sarcoma","enrollment":18},{"nctId":"NCT05700630","phase":"PHASE1","title":"Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-07-15","conditions":"HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency","enrollment":""},{"nctId":"NCT06223646","phase":"PHASE1, PHASE2","title":"A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Novatim Immune Therapeutics (Zhejiang) Co., Ltd.","startDate":"2024-01-11","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT04715217","phase":"PHASE1, PHASE2","title":"Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma","status":"UNKNOWN","sponsor":"Shanxi Province Cancer Hospital","startDate":"2021-01-04","conditions":"Lymphoma, B-Cell","enrollment":24},{"nctId":"NCT04714827","phase":"PHASE1, PHASE2","title":"Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanxi Province Cancer Hospital","startDate":"2021-01-22","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT05070156","phase":"EARLY_PHASE1","title":"B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tongji University","startDate":"2021-10-29","conditions":"Advanced Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT05749133","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM","status":"UNKNOWN","sponsor":"XuYan","startDate":"2023-04-10","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":18},{"nctId":"NCT04920617","phase":"PHASE2","title":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","startDate":"2021-06-18","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma","enrollment":102},{"nctId":"NCT04860817","phase":"EARLY_PHASE1","title":"A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL","status":"WITHDRAWN","sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","startDate":"2021-12-01","conditions":"T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT04714593","phase":"PHASE1, PHASE2","title":"Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Shanxi Province Cancer Hospital","startDate":"2021-01-15","conditions":"Acute Lymphocytic Leukemia， B-Cell","enrollment":24},{"nctId":"NCT03642496","phase":"EARLY_PHASE1","title":"Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2018-08-19","conditions":"B-Cell Malignancies","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Low-dose CAR-T cells group","genericName":"Low-dose CAR-T cells group","companyName":"Guangzhou Women and Children's Medical Center","companyId":"guangzhou-women-and-children-s-medical-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Low-dose CAR-T cells are engineered T lymphocytes expressing chimeric antigen receptors at reduced cell doses to target and kill cancer cells while potentially reducing toxicity. Used for Hematologic malignancies (specific indication not specified in available data).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}